X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs ALKEM LABORATORIES - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA ALKEM LABORATORIES DISHMAN PHARMA/
ALKEM LABORATORIES
 
P/E (TTM) x 25.1 - - View Chart
P/BV x 3.3 6.7 50.0% View Chart
Dividend Yield % 0.7 0.6 102.5%  

Financials

 DISHMAN PHARMA   ALKEM LABORATORIES
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
ALKEM LABORATORIES
Mar-16
DISHMAN PHARMA/
ALKEM LABORATORIES
5-Yr Chart
Click to enlarge
High Rs3741,589 23.6%   
Low Rs1291,232 10.5%   
Sales per share (Unadj.) Rs197.8417.5 47.4%  
Earnings per share (Unadj.) Rs21.256.3 37.7%  
Cash flow per share (Unadj.) Rs34.764.7 53.7%  
Dividends per share (Unadj.) Rs2.0012.70 15.7%  
Dividend yield (eoy) %0.80.9 88.3%  
Book value per share (Unadj.) Rs179.9292.9 61.4%  
Shares outstanding (eoy) m80.69119.57 67.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.33.4 37.7%   
Avg P/E ratio x11.925.1 47.4%  
P/CF ratio (eoy) x7.221.8 33.2%  
Price / Book Value ratio x1.44.8 29.1%  
Dividend payout %9.422.6 41.8%   
Avg Mkt Cap Rs m20,306168,653 12.0%   
No. of employees `0000.8NA-   
Total wages/salary Rs m5,3559,171 58.4%   
Avg. sales/employee Rs Th19,252.7NM-  
Avg. wages/employee Rs Th6,459.5NM-  
Avg. net profit/employee Rs Th2,064.1NM-  
INCOME DATA
Net Sales Rs m15,96149,915 32.0%  
Other income Rs m2651,645 16.1%   
Total revenues Rs m16,22651,561 31.5%   
Gross profit Rs m4,1038,482 48.4%  
Depreciation Rs m1,0911,006 108.4%   
Interest Rs m944671 140.8%   
Profit before tax Rs m2,3348,451 27.6%   
Minority Interest Rs m0-114 0.0%   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6241,606 38.8%   
Profit after tax Rs m1,7116,731 25.4%  
Gross profit margin %25.717.0 151.3%  
Effective tax rate %26.719.0 140.6%   
Net profit margin %10.713.5 79.5%  
BALANCE SHEET DATA
Current assets Rs m11,01827,062 40.7%   
Current liabilities Rs m9,51715,324 62.1%   
Net working cap to sales %9.423.5 40.0%  
Current ratio x1.21.8 65.6%  
Inventory Days Days11067 166.1%  
Debtors Days Days3541 84.4%  
Net fixed assets Rs m16,30412,610 129.3%   
Share capital Rs m161239 67.5%   
"Free" reserves Rs m12,90734,490 37.4%   
Net worth Rs m14,51635,027 41.4%   
Long term debt Rs m4,1891,212 345.8%   
Total assets Rs m29,80554,387 54.8%  
Interest coverage x3.513.6 25.5%   
Debt to equity ratio x0.30 834.4%  
Sales to assets ratio x0.50.9 58.3%   
Return on assets %8.913.6 65.5%  
Return on equity %11.819.2 61.3%  
Return on capital %17.524.9 70.5%  
Exports to sales %24.812.9 191.5%   
Imports to sales %3.73.1 121.1%   
Exports (fob) Rs m3,9566,461 61.2%   
Imports (cif) Rs m5961,540 38.7%   
Fx inflow Rs m4,9526,563 75.4%   
Fx outflow Rs m6973,012 23.1%   
Net fx Rs m4,2553,552 119.8%   
CASH FLOW
From Operations Rs m2,7867,259 38.4%  
From Investments Rs m-1,5291,864 -82.0%  
From Financial Activity Rs m-941-9,273 10.1%  
Net Cashflow Rs m316-150 -210.9%  

Share Holding

Indian Promoters % 61.4 66.9 91.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 33.1 11.2%  
FIIs % 12.7 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 0.0 -  
Shareholders   46,261 68,381 67.7%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   NOVARTIS  ASTRAZENECA PHARMA  NATCO PHARMA  SHASUN PHARMA  IPCA LABS  

Compare DISHMAN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 219 Points Lower; Energy and Auto Stocks Witness Selling(Closing)

After witnessing volatile trades during the day, Indian share markets ended their session on a negative note. Losses were largely seen in the oil & gas sector, auto sector.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

This Behaviour is Injurious to Wealth Building(Sector Info)

Jun 13, 2018

Blindly following the herd can be the biggest wealth destroyer.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS